
IFN-γ (ng/ml)
300
200
100
0
Mouse IgG2a C1.18.4
Rat IgG2a 2A3
anti-PD-1 RMP1-14
3847
12191
13396
13398
13399
12195
13401
13402
13403
13404
13405
12228
13406
13407
13408
13409
ns
*
**
***
****

FIG. 1



FIG. 2


Pembrolizumab
Nivolumab
Buffer
12228
13406
13407
13408
13409
100nM mPD-L1
Anti-PD1
hFc Blocking
mPD1
nm
0.2
0
-0.2
-0.4
-0.6
-0.8
-1.0
-1.2
-1.4
-1.6
-1.8
-2.0
0
200
400
600
800
1000
1200
1400
Time (s)

FIG. 3A


Pembrolizumab
Nivolumab
Buffer
12228
13406
13407
13408
13409
100nM mPD-L2
Anti-PD1
hFc Blocking
mPD1
nm
0.2
0
-0.2
-0.4
-0.6
-0.8
-1.0
-1.2
-1.4
-1.6
-1.8
0
200
400
600
800
1000
1200
1400
Time (s)

FIG. 3B


12228
13406
13407
13408
13409
Pembrolizumab
Nivolumab
100nM hPD-L1
Anti-PD1
Buffer
hFc Blocking
hPD1
nm
1.0
0.5
0
-0.5
-1.0
-1.5
-2.0
0
200
400
600
800
1000
1200
1400
Time (s)

FIG. 4A-1


12228
13406
13407
13408
13409
Pembrolizumab
Nivolumab
300nM hPD-L1
Anti-PD1
Buffer
hFc Blocking
hPD1
nm
1.0
0.5
0
-0.5
-1.0
-1.5
0
200
400
600
800
1000
1200
1400
Time (s)

FIG. 4A-2


12228
13406
13407
13408
13409
Pembrolizumab
Nivolumab
100nM hPD-L2
Anti-PD1
Buffer
hFc Blocking
hPD1
nm
1.0
0.5
0
-0.5
-1.0
-1.5
0
200
400
600
800
1000
1200
1400
Time (s)

FIG. 4B-1


12228
13406
13407
13408
13409
Pembrolizumab
Nivolumab
300nM hPD-L2
Anti-PD1
Buffer
hFc Blocking
hPD1
nm
1.0
0.5
0
-0.5
-1.0
-1.5
0
200
400
600
800
1000
1200
1400
Time (s)

FIG. 4B-2


12228
13406
13407
13408
13409
Pembrolizumab
Nivolumab
Buffer
Anti-PD1
Buffer
hFc Blocking
hPD1
nm
1.0
0.5
0
-0.5
-1.0
-1.5
0
200
400
600
800
1000
1200
1400
Time (s)

FIG. 4C


Tumor Weights
Grams
2.5
2.0
1.5
1.0
0.5
0.0
2A3
MOPC-21
RMP1-14
13407
2A3
MOPC-21
RMP1-14
13407

FIG. 5